Table 5.

PONV management in women undergoing CPC vs. ERAS in minimally invasive non-hysterectomy procedures

Antiemetic Use	CPC (n=214)	ERAS (n=196)	P-value
Pre-operative Medications	n=66/214 (30.8)	n=193/196 (98.5)	<.001
Perphenazine	12 (5.6)	192 (98.0)	<.001
Scopolamine patch	38 (17.8)	28 (14.3)	.339
Aprepitant	43 (20.1)	28 (14.3)	.121
Pre-operative Doses	0.43 0.71	1.25 0.6	<.001
Intra-operative Medications	n=213/214 (99.5)	n=190/196 (96.9)	.043
Dexamethasone	191 (89.3)	173 (88.3)	.752
Ondansetron	213 (99.5)	190 (96.9)	.058
Intra-operative Doses	2.36 0.6	1.96 0.4	<.001
PACU Medications	n=77/214 (36.0)	n=41/196 (20.9)	.001
Dexamethasone	28 (13.1)	1 (0.5)	<.001
Ondansetron	71 (33.2)	39 (19.9)	.002
Prochlorperazine	15 (7.0)	4 (2.0)	.017
PACU Doses	0.57 0.9	0.25 0.6	<.001
Total Doses	3.37 1.3	3.48 1.0	.346

CPC, conventional peri-operative care; ERAS, enhanced recovery after surgery; PONV, post-operative nausea and vomiting

Data are n (%) or mean ± standard deviation